|
Characteristics
|
N (%)
|
|---|
|
Age, years (range)
|
56.8 (39.4–83.5)
|
|
ECOG Performance Status ≤2
|
22 (100)
|
|
IHC molecular markers
|
|
Primary tumor tissues
|
22
|
|
ER+ and/or PgR+
|
15 (68.2)
|
|
ER- and/or PgR-
|
7 (31.8)
|
|
HER2 1+/SISH or FISH+
|
3 (13.6)
|
|
HER2 2+/SISH or FISH+
|
2 (9.1)
|
|
HER2 3+
|
17 (77.3)
|
|
Metastatic tumor tissues
|
9
|
|
ER+ and/or PgR+
|
6 (66.7)
|
|
ER- and/or PgR-
|
3 (33.3)
|
|
HER2 1+/SISH or FISH+
|
1 (11.1)
|
|
HER2 2+/SISH or FISH+
|
3 (33.3)
|
|
HER2 3+
|
5 (55.6)
|
|
Previous lines of therapy
|
|
1
|
14 (63.6)
|
|
2
|
7 (31.8)
|
|
3
|
1 (4.5)
|
|
Pertuzumab as first line treatment
|
|
Yes
|
9 (40.9)
|
|
No
|
13 (59.1)
|
|
Dominant Metastatic sites
|
|
Liver
|
3 (13.6)
|
|
Lung
|
3 (13.6)
|
|
Bone
|
5 (22.7)
|
|
Soft tissues
|
7 (31.9)
|
|
Brain
|
4 (18.2)
|
|
Number of metastatic sites per patient
|
|
1
|
8 (36.6)
|
|
2
|
9 (40.9)
|
|
≥ 3
|
5 (22.7)
|
- Previous therapy lines included: Lapatinib plus Capecitabine, Trastuzumab plus Vinorelbine, Trastuzumab plus Carboplatin
- IHC Immunoistochemistry, ER Estrogen receptor, PgR Progesterone receptor, SISH/FISH Silver in situ hybridization/Fluorescent in situ hybridization
